Is Plus Therapeutics Inc (PSTV) overvalued? · P/E 0.2, rev $5.8M
Plus Therapeutics Inc (PSTV) is a biotechnology company listed on NASDAQ.
This page asks whether Plus Therapeutics Inc (PSTV) looks expensive on cached numbers — not a short thesis.
Latest reported PSTV revenue for 2024-12-31 was $5.8M. Net income was -$13.0M. Revenue was up 18.5% from 2023-12-31 to 2024-12-31. PSTV currently screens at market cap $29.7M and trailing P/E 0.2.
PSTV currently screens at market cap $29.7M and trailing P/E 0.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PSTV 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PSTV stock page for the full model, not this heading.
Not investment advice.